Core Insights - NurExone Biologic Inc. is actively participating in two significant international conferences in March 2026, focusing on advancements in nanotechnology and regenerative therapies [1][2][3] Company Updates - Dr. Lior Shaltiel, CEO of NurExone, emphasizes the importance of engaging with scientific and investor communities through participation in NANO.IL.2026 and the Advanced Therapies Congress [2][3] - Mr. Jacob Licht will step down from his roles at NurExone and Exo-Top Inc. at the end of March 2026 for personal reasons, with the management team taking over his responsibilities temporarily [4] Product and Market Focus - NurExone is developing exosome-based regenerative therapies, with its lead product ExoPTEN showing promising preclinical data for treating acute spinal cord and optic nerve injuries, which are part of multi-billion-dollar markets [5] - The company has received Orphan Drug Designation, facilitating its roadmap towards clinical trials in the U.S. and Europe [5]
NurExone to Showcase Its Regenerative Medicine Platform at NANO.IL.2026 and Advanced Therapies Congress in March 2026 and Provides Corporate Update
Globenewswire·2026-02-27 21:03